Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Linaclotide (Linzess) Peptide
Guanylate cyclase-C agonist peptide for IBS-C and chronic constipation.
What is Linaclotide (Linzess)?
Linaclotide (Linzess) is a gc-c agonist · gastrointestinal peptide studied for ibs-c and chronic idiopathic constipation. Below is an educational overview of Linaclotide (Linzess) peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Plain-Language Label Highlights
Brand names: Linzess
Chronic idiopathic constipation, IBS with constipation, and functional constipation in children 6+.
A daily capsule taken on an empty stomach that pulls fluid into the intestines to soften stool and ease passage.
Do NOT give to children under 2 years — risk of severe dehydration.
- •Diarrhea
- •Gas
- •Abdominal pain
- •Bloating
- •Severe diarrhea leading to dehydration
- •Allergic reactions
- •Children under 2 years
- •Known mechanical GI obstruction
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Linaclotide (Linzess) Mechanism of Action
14-amino-acid peptide that activates intestinal guanylate cyclase-C, increasing cGMP and chloride/bicarbonate secretion into the gut lumen — accelerating transit and reducing visceral pain.
Linaclotide (Linzess) Research Areas & Benefits
Linaclotide (Linzess) Dosage & Common Research Protocols
72–290 mcg orally once daily on empty stomach.
Protocols summarized for educational reference from published research. Not dosing guidance.
Linaclotide (Linzess) Studies & Cited Research
Linaclotide phase 3 trials
Improved abdominal pain and bowel function in IBS-C.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Linaclotide (Linzess) Side Effects & Safety Considerations
- •FDA-approved.
- •Contraindicated in children <2 years; diarrhea common.
Explore more peptides
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.